Clinical Trial: Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects with Advanced Solid Tumors Expressing Somatostatin Receptors

U.S., Feb. 22 -- ClinicalTrials.gov registry received information related to the study (NCT06840821) titled 'Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects with Advanced Solid Tumors Expressing Somatostatin Receptors' on Feb. 07.

Brief Summary: This is a multicenter, open-label, single-arm, dose-escalation and dose-expansion Phase I/II study to evaluate the safety, tolerability and preliminary anti-tumor activity of MB0151 in adult subjects (at least 18 years old) with advanced solid tumors. This study includes two phases: dose escalation and dose expansion. In this study, the protocol of accelerated titration combined with i3+3 is used for dose escalation,administered intravenously eve...